FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks
The 32-mg, single intravenous dose of the anti-nausea drug Zofran will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.
Recent Videos
Related Content
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Podcast
Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
